Stock·NYSE·Industrials
Johnson Controls International (JCI)
- Market cap
- $94.42B
- Dividend yield
- 1.01%
- Street target
- $170.50median of 22 analysts
- 52-week range
- $108.41 $160.41
JCI stock forecast today
Where JCI stands today, and what CleaRank Financial AI makes of it.
JCI at a glance
Johnson Controls International (JCI): Buy, 65/100 on CleaRank's AI score.
- Trend Up: the price is above both its 50- and 200-day moving averages ($146.85 and $140.46).
- Earnings JCI beat estimates in 8 of its last 8 quarters, yet fell the next day after 1 of those beats.
- Insiders Insiders sold $40.8M and bought $1.0M over the last 18 months.
Figures as of October 27, 2026.
CleaRank Financial AI
Johnson Controls International (JCI) carries a CleaRank rating of Buy and a model score of 65/100.
Trend is the strongest contributor: the price sits 10.98% above its 200-day average and 6.15% above its 50-day average, and the 50-day average is 4.55% above the 200-day. The 50-day average is $146.85 and the 200-day is $140.46. Across the past year, the price rose 37.89%.
Only on CleaRank
Figures we compute ourselves from JCI's own price, earnings and insider-filing history. Tap one to see it in context.
JCI stock price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
4/4Price above its 50-day average ›
The price of $155.88 is 6.1% above the 50-day simple moving average of $146.85.Price above its 200-day average ›
The price is 11.0% above the 200-day simple moving average of $140.46.50-day average above the 200-day ›
The 50-day average ($146.85) is 4.5% above the 200-day average ($140.46), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 91% of its 52-week range, between $108.41 and $160.41.
JCI share price
Pick a period: each tab shows how far JCI has moved over it, to the last close.
Today's trading
Where JCI sits inside today's range and its 52-week range.
JCI fundamentals and valuation
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
4/4P/S below the sector median ›
The price-to-sales ratio of 3.78 is 5.6% below the sector median of 4.0.Profitable over the last 12 months ›
Net income over the last 12 months was $3.7B on revenue of $25.0B, a net margin of 14.6%.Beat estimates in most recent reports ›
JCI beat the EPS estimate in 8 of its last 8 reports.Pays a dividend ›
The trailing dividend yield is 1.01%, or $1.57 a share a year.
Key statistics
The headline figures for JCI.
As of October 27, 2026, JCI trades at $155.88, with a market value of $94.42B and a dividend yield of 1.01%.
What the numbers say
CleaRank Financial AI's reading of JCI's valuation, growth and risks.
On sales, the price-to-sales ratio of 3.78 is 5.5% below the sector median of 4.0. The market capitalisation stands at $94.4B.
JCI is growing more slowly than its sector. Revenue rose 9.30% in the latest quarter year on year, compared with a sector median of 11.7%. The company converts sales into profit at a net margin of 14.32% and an operating margin of 15.88%. Its return on equity of 14.33% is below the sector median of 17.8%. On the balance sheet, debt-to-equity stands at 0.70, and the trailing dividend yield is 1.01%, equal to $1.57 a share per year.
JCI's most recent report, on July 29, 2026, beat the estimate by 9.23%, with EPS of $1.42 against an estimate of $1.30. The market agreed: the stock rose 3.20% the following session.
Across its last 8 reports, JCI beat the estimate every time; even so, 1 of those 8 beats was followed by a lower share price the next session. Looking ahead, analysts expect EPS of $5.07 this fiscal year (growth of 34.9%) and $6.13 the year after (growth of 20.9%).
The average daily move is 2.15%, and the beta against the S&P 500 is 1.28.
JCI against the Industrials sector
How JCI compares with the median Industrials stock CleaRank tracks.
Price to sales vs sector: On price-to-sales, the yardstick used here in place of P/E, JCI trades at 3.78x, -6% versus the sector average of 4.00x.
Return vs XLI: Since May 15, 2025, JCI has gained 61.1% against a gain of 18.1% for XLI.
Performance against XLI
JCI and the Industrials sector fund over the same days.
Revenue and earnings
How much JCI sells, and how much of it becomes profit.
Revenue growth: Revenue grew 2.8% in FY2025 to $23.6B, from $23.0B a year earlier.
Profit margin: The net margin was 14.9% in FY2025, up from 8.3% the year before.
Profitable: JCI earned $3.5B in FY2025.
Earnings reality check
Did JCI beat what analysts expected, and how did the stock react?
Earnings record: JCI beat the analyst estimate in 8 of the last 8 quarters.
Market reaction: The stock fell in the first session after 1 of those 8 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Jul 29, 2026after close | $1.30 | $1.42 | +9.23% | +3.20% | +10.21% |
| May 6, 2026after close | $1.12 | $1.19 | +6.25% | -2.72% | +0.46% |
| Feb 4, 2026after close | $0.84 | $0.89 | +5.95% | +2.34% | +8.86% |
| Nov 5, 2025after close | $1.20 | $1.26 | +5.00% | +1.15% | +1.49% |
| Jul 29, 2025after close | $1.01 | $1.05 | +3.96% | +0.76% | +1.55% |
| May 7, 2025after close | $0.80 | $0.82 | +2.50% | +1.66% | +7.35% |
| Feb 5, 2025after close | $0.59 | $0.64 | +8.47% | +2.31% | +3.51% |
| Nov 6, 2024after close | $1.25 | $1.28 | +2.40% | +0.54% | +5.20% |
As of October 27, 2026, JCI has beaten the analyst EPS estimate in 8 of its last 8 reported quarters and fell in the first trading session after 1 of those beats; its latest report, on July 29, 2026, came in 9.23% above the estimate and the stock moved +3.20% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
JCI AI analysis and technical indicators
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
3/3RSI not overbought or oversold ›
The 14-day RSI is 58.2, in neutral territory.RSI above 50 ›
An RSI of 58.2 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank Financial AI analysis of JCI
The score, the reasoning behind it, and what could move the price next.
Both moving averages sit under the price, which is the shape of an uptrend for Johnson Controls International (JCI): the price of $155.88 is 6.15% above the 50-day average ($146.85) and 10.98% above the 200-day average ($140.46). The price sits near the top of its 52-week range, 2.82% below the high of $160.41 and 43.79% above the low of $108.41. With the 50-day average 4.55% above the 200-day, the averages themselves are lined up for an uptrend.
The recent returns are all positive: the price rose 11.12% over the past three months, rose 10.09% over the past six months and rose 37.89% over the past year. Volume in the last session ran 41.3% above its average, on a day the price rose 5.68%. The 14-day RSI of 58.2 is in the neutral zone, and the MACD line is positive.
Earnings beat ›
The July 29, 2026 report beat the EPS estimate by 9.23%, and the share price rose 3.20% in the first session after it.
Source: Earnings report, July 29, 2026New analyst coverage ›
Wells Fargo started coverage at Overweight on September 25, 2026.
Source: Analyst action, Wells Fargo, September 25, 2026
Rating reaffirmed ›
Mizuho kept its Neutral rating on October 15, 2026.
Source: Analyst action, Mizuho, October 15, 2026
- The two levels to watch are the 52-week high at $160.41, just above the price, and the 20-day EMA at $149.65, just below it.
- A 14-day RSI of 58.2 is neutral, and the MACD line is positive. Readings above 70 or below 30 would signal stretched momentum.
- The share price rose 3.20% in the first session after the July 29, 2026 report. Across its last 8 reports, JCI has beaten estimates each time.
The uptrend rests on JCI staying above its 50-day average at $146.85 and its 200-day average at $140.46; a close below the 50-day would be the first crack in it. On a pullback, the first level the price would meet is the 20-day EMA at $149.65.
The next level overhead is the 52-week high, at $160.41.
Technical indicators
Momentum and trend for JCI, from its daily closes.
As of October 27, 2026, with JCI at $155.88, its 14-day RSI is 58.2 (neutral territory), its 50-day simple moving average is $146.85 and its 200-day is $140.46.
Calculated by CleaRank on daily closes as of October 27, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26). How we calculate these
What JCI moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 27, 2026, JCI's 1-year correlation of daily returns is +0.62 with S&P 500 (SPY), +0.60 with Nasdaq 100 (QQQ), +0.09 with Bitcoin (BTC) and +0.11 with gold (XAU).
JCI price target and analyst forecast
The analysts' target range and how their ratings split.
Analysts checks
3/3Most analysts rate it a buy ›
12 of 22 analysts rate it a buy or strong buy, 8 a hold and 2 a sell.Median target above the price ›
The median 12-month target of $170.50 is 9.4% above the price.More buy ratings than three months ago ›
12 of 22 rate it a buy now, against 11 of 21 three months ago.
JCI Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 15, 2026 | Mizuho | Maintains | Neutral |
| Oct 14, 2026 | RBC Capital | Maintains | Sector Perform |
| Oct 12, 2026 | Citigroup | Maintains | Neutral |
| Oct 8, 2026 | B of A Securities | Maintains | Buy |
| Sep 25, 2026 | Wells Fargo | Initiates | Overweight |
| Sep 2, 2026 | Morgan Stanley | Maintains | Overweight |
As of October 27, 2026, 22 Wall Street analysts cover JCI: 12 rate it a buy or strong buy, 8 a hold and 2 a sell or strong sell. Their 12-month price targets range from $129.00 to $193.00. The median JCI price target is $170.50, 9.4% above the price of $155.88.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
JCI trade plan: entry, stop loss and targets
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
JCI trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from JCI's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much JCI tends to move, against the market and on its own.
JCI price history and drawdowns
JCI's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
2/4Average daily move under 2% ›
The price has moved 2.15% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 41.4%, from November 2019 to March 2020, regained by October 2020.Most 1-year holds ended higher ›
65% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $41,666, against $42,015 in the S&P 500 (SPY).
JCI Drawdowns & Recovery
As of October 27, 2026, JCI's worst peak-to-trough fall over the last 10 years with dividends reinvested was -41.4% (November 2019 to March 2020); it regained that peak by October 2020, 7 months after the low, and 65% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into JCI in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: JCI trailed the S&P 500 over this period: $41,666 against $42,015.
A $10,000 investment in JCI in October 2016 would be worth about $41,666 today with dividends reinvested, compared with about $42,015 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to JCI, and which have not.
Strongest month, July: an average of +4.94%, up in 9 of 10 years.
Weakest month, March: an average of -3.04%, up in 5 of 10 years.
This month, October: has averaged +0.89%, up in 4 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, JCI's strongest calendar month has been July (average +4.94%, up in 9 of 10 years) and its weakest March (average -3.04%, up in 5 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
JCI stock price prediction 2030
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in JCI, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 4-year Monte Carlo simulation, based on 10 years of price history, projects that a $10,000 investment in JCI today could grow to about $13,942 by 2030 in the base case, with a 90th-percentile outcome near $28,894 and a 10th-percentile outcome around $6,727. The simulation models price only; at today's 1.01% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
JCI Stock Price Prediction 2030: Simulated Scenarios
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $217 for JCI by 2030 in the base case, from $156 today (1.4x over 4 years). The 10th-percentile path ends near $105. These are outcomes of a Monte Carlo simulation run on JCI's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $118 | $169 | $244 | |
| 2028 | $110 | $184 | $308 | |
| 2029 | $106 | $200 | $376 | |
| 2030 | $105 | $217 | $450 |
Method: a lognormal simulation of JCI's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles. How the simulation works
JCI insider trading
What the people running the company have bought and sold.
JCI insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Net insider selling: Insiders bought $1.0M on the open market and sold $40.8M.
As of October 27, 2026, JCI insiders reported 19 open-market sales worth $40.8M and 1 open-market purchase worth $1.0M over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Aug 19, 2026 | Pierre E Cohade
Director
|
Sell | 3.3K | $487.7K |
| Aug 4, 2026 | Lei Zhang Schlitz
Officer
|
Sell | 23.4K | $3.6M |
| Jun 9, 2026 | Todd M Grabowski
Officer
|
Sell | 1.8K | $263.2K |
| Jun 8, 2026 | Irene M Esteves
Director
|
Grant | 937 | - |
| May 14, 2026 | Todd M Grabowski
Officer
|
Sell | 4.3K | $621.9K |
| May 8, 2026 | Lei Zhang Schlitz
Officer
|
Sell | 88.8K | $12.5M |
| May 8, 2026 | Lei Zhang Schlitz
Officer
|
Option | 62.8K | $3.9M |
| Mar 4, 2026 | Timothy M Archer
Director
|
Grant | 1.3K | - |
| Mar 4, 2026 | Pierre E Cohade
Director
|
Grant | 1.3K | - |
| Mar 4, 2026 | Webster Roy Dunbar
Director
|
Grant | 1.3K | - |
| Mar 4, 2026 | Gretchen R Haggerty
Director
|
Grant | 1.3K | - |
| Mar 4, 2026 | Ayesha Khanna
Director
|
Grant | 1.3K | - |
| Mar 4, 2026 | Seetarama Swamy Kotagiri
Director
|
Grant | 1.3K | - |
| Mar 4, 2026 | Carl Juergen Tinggren
Director
|
Grant | 1.3K | - |
| Mar 4, 2026 | Mark P Vergnano
Director
|
Grant | 1.3K | - |
| Mar 4, 2026 | John D Young
Director
|
Grant | 1.3K | - |
| Feb 23, 2026 | Daniel C Mcconeghy
Officer
|
Sell | 3.6K | $513.2K |
| Feb 6, 2026 | Todd M Grabowski
Officer
|
Sell | 6.1K | $816.1K |
| Feb 5, 2026 | Mark P Vergnano
Director
|
Buy | 7.7K | $1.0M |
| Feb 5, 2026 | Mark P Vergnano
Director
|
Grant | 7.7K | - |
| Jan 26, 2026 | Susan Mckee Hughes
Officer
|
Grant | 23.2K | - |
| Dec 10, 2025 | John Donofrio
General Counsel
|
Sell | 21.6K | $2.5M |
| Dec 5, 2025 | John Donofrio
General Counsel
|
Grant | 21.8K | $2.5M |
| Dec 5, 2025 | Todd M Grabowski
Officer
|
Grant | 1.7K | $197.8K |
| Dec 5, 2025 | Richard Lek
Officer
|
Grant | 1.2K | $141.3K |
| Dec 5, 2025 | Daniel C Mcconeghy
Officer
|
Grant | 4.9K | $565.4K |
| Dec 5, 2025 | Anuruddha Rathninde
Officer
|
Grant | 16.8K | $1.9M |
| Dec 5, 2025 | Lei Zhang Schlitz
Officer
|
Grant | 27.2K | $3.1M |
| Dec 5, 2025 | Marc Vandiepenbeeck
Chief Financial Officer
|
Grant | 4.9K | $554.1K |
| Dec 1, 2025 | John Donofrio
General Counsel
|
Grant | 4.8K | - |
| Dec 1, 2025 | Todd M Grabowski
Officer
|
Grant | 3.8K | - |
| Dec 1, 2025 | Brandt Julie M Heuer
President
|
Grant | 4.4K | - |
| Dec 1, 2025 | Richard Lek
Officer
|
Grant | 2.2K | - |
| Dec 1, 2025 | Daniel C Mcconeghy
Officer
|
Grant | 1.1K | - |
| Dec 1, 2025 | Anuruddha Rathninde
Officer
|
Grant | 3.7K | - |
| Dec 1, 2025 | Christopher M Scalia
Officer
|
Grant | 4.1K | - |
| Dec 1, 2025 | Lei Zhang Schlitz
Officer
|
Grant | 6.0K | - |
| Dec 1, 2025 | Marc Vandiepenbeeck
Chief Financial Officer
|
Grant | 7.2K | - |
| Dec 1, 2025 | Joakim Weidemanis
Chief Executive Officer
|
Grant | 26.1K | - |
| Nov 21, 2025 | Lei Zhang Schlitz
Officer
|
Sell | 32.0K | $3.6M |
| Nov 13, 2025 | Jean S. Blackwell
Director
|
Grant | 4.9K | - |
| Nov 6, 2025 | Lei Zhang Schlitz
Officer
|
Sell | 10.5K | $1.3M |
| Sep 3, 2025 | Daniel C Mcconeghy
Officer
|
Sell | 5.9K | $625.6K |
| Sep 3, 2025 | Daniel C Mcconeghy
Officer
|
Option | 5.9K | $470.6K |
| Sep 2, 2025 | Nathan D Manning
Officer
|
Sell | 1.4K | $149.4K |
| Aug 1, 2025 | Nathan D Manning
Officer
|
Sell | 1.4K | $147.4K |
| Jul 14, 2025 | Christopher M Scalia
Officer
|
Grant | 23.5K | $2.5M |
| Jul 1, 2025 | Nathan D Manning
Officer
|
Sell | 1.4K | $149.1K |
| Jun 6, 2025 | Anuruddha Rathninde
President
|
Sell | 15.0K | $1.5M |
| Jun 2, 2025 | Nathan D Manning
Officer
|
Sell | 1.4K | $143.5K |
| May 23, 2025 | George R Oliver Sr
Director
|
Grant | 360 | - |
| May 9, 2025 | George R Oliver Sr
Director
|
Sell | 100.0K | $9.2M |
| May 9, 2025 | George R Oliver Sr
Director
|
Grant | 2.6K | - |
| May 8, 2025 | Marc Vandiepenbeeck
Chief Financial Officer
|
Sell | 28.3K | $2.6M |
| May 8, 2025 | Marc Vandiepenbeeck
Chief Financial Officer
|
Option | 23.0K | $1.0M |
| May 1, 2025 | Nathan D Manning
Officer
|
Sell | 1.4K | $123.6K |
Source: TwelveData, from reported insider filings
JCI stock forecast: questions people ask
Answered from the figures on this page, as of October 27, 2026.